PT -期刊文章盟Zuzana Nedelska AU -斯科特Przybelski盟-盖Lesnick AU -克里斯托弗•施瓦兹AU - Val劳盟玛丽Machulda AU - David Knopman AU -沃尔特·克雷默AU -罗纳德·彼得森AU -克利福德杰克盟Kejal Kantarci TI -脑组织代谢物在基线与大夫人β-amyloid堆积速率从串行宠物临床正常老年人(S35.004) DP - 2017年4月18日TA -神经病学PG - S35.004 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/S35.004.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/S35.004.full所以Neurology2017 4月18日;首页88 AB -目的:确定基线质子核磁共振谱(1 h-mrs)代谢物测量与β-amyloid积累的速率串行正电子发射断层扫描(PET)在临床正常老年人(CN)。背景:改变脑组织代谢物比值在1 h-mrs CN与β-amyloid更高和更高的患认知障碍的风险。代谢物夫人比率之间的关系随着时间的推移和β-amyloid积累在CN来自普通人群是未知的。设计/方法:梅奥诊所研究衰老的参与者年龄超过50岁(n = 646),在临床上被诊断为正常基线,接受3 t 1 h-mrs后扣带体素和纵向11 c匹兹堡化合物B(加以)宠物。组织代谢物N-acetylaspartate(乙酰天冬氨酸;标记的神经元生存能力)、胆碱(曹;膜完整性的标志)和肌醇(mI;胶质活动和炎症)的标志是由肌酸比例(Cr),一个内部参考。我们符合线性混合模型预测β-amyloid积累随着时间的推移使用串行皮质加以标准摄入值比率(SUVr)作为基线的函数1 h-mrs代谢物比率,和评估性和载脂蛋白E (APOE)状态如何影响代谢物之间的关系比和β-amyloid沉积。结果:平均(SD)皮质加以SUVr是1.46(0.30)以35%的人群有较高加以吸收(SUVr> 1.4)。高mI / Cr (p = 0.01)和较低的NAA / mI (p = 0.004)比率是关联到一个更大的增长率加以SUVr在调整了年龄和性别。 Neither APOEɛ4 status nor sex differences modified the relationship between baseline metabolite ratios and PiB SUVr. There was no association between the baseline Cho/Cr and β-amyloid deposition.Conclusions: 1H-MRS is a non-invasive MR technique that can detect metabolic alterations associated with a greater increase in β-amyloid deposition over time. A low NAA/mI ratio points to a greater β-amyloid accumulation rate in CN and may have an important role in predicting preclinical AD pathology.Disclosure: Dr. Nedelska has nothing to disclose. Dr. Przybelski has nothing to disclose. Dr. Lesnick has nothing to disclose. Dr. Schwarz has nothing to disclose. Dr. Lowe received personal compensation for activities with Bayer Pharmaceuticals as a consultant. Dr. Machulda has nothing to disclose. Dr. Knopman has received personal compensation for activities with Lundbeck Pharmaceuticals.Dr. Knopman has received research support from Lilly Pharmaceuticals, Biogen and TauRX. Dr. Kremers has nothing to disclose. Dr. Petersen received personal compensation for activities with Merck, Roche, Genentech, Biogen, and Eli Lilly and Co. Dr. Jack has received personal compensation for activities with Janssen Research & Development, LLC by providing consulting services. Dr. Jack has received research support from the National Institutes of Health (R01-AG011378, RO1-AG041851, RO1-AG037551. Dr. Katarci has received royalty payments from Takeda.